Cytomed Therapeutics Limited (GDTC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2024 | 12-2023 | 12-2022 | |
| Cash Flows From Operating Activities | |||
| Net Income | -1,846 | -3,132 | -2,335 |
| Depreciation Amortization | 246 | 289 | 293 |
| Accounts payable and accrued liabilities | -61 | 84 | 190 |
| Other Working Capital | -44 | 80 | 82 |
| Other Operating Activity | -278 | 79 | 726 |
| Operating Cash Flow | $-1,984 | $-2,602 | $-1,043 |
| Cash Flows From Investing Activities | |||
| Change In Deposits | 1,828 | -2,100 | N/A |
| PPE Investments | -1,025 | -44 | -353 |
| Purchase Sale Intangibles | -69 | N/A | N/A |
| Other Investing Activity | 21 | 0 | 0 |
| Investing Cash Flow | $825 | $-2,145 | $-353 |
| Cash Flows From Financing Activities | |||
| Change In Short Term Borrowing | N/A | N/A | 224 |
| Debt Repayment | -7 | -6 | -6 |
| Common Stock Issued | N/A | 8,571 | 912 |
| Other Financing Activity | -40 | -288 | -408 |
| Financing Cash Flow | $-48 | $8,277 | $723 |
| Exchange Rate Effect | 89 | -10 | -22 |
| Beginning Cash Position | 4,556 | 1,197 | 1,875 |
| End Cash Position | 3,438 | 4,718 | 1,179 |
| Net Cash Flow | $-1,118 | $3,520 | $-696 |
| Free Cash Flow | |||
| Operating Cash Flow | -1,984 | -2,602 | -1,043 |
| Capital Expenditure | -1,025 | -44 | -354 |
| Free Cash Flow | -3,009 | -2,646 | -1,397 |